Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration
10 lipca 2026 zaktualizowane przez: Shengdi Chen, Ruijin Hospital
A Study on the Therapeutic Effects and Target Exploration of Temporal Interference-Based Noninvasive Deep Brain Stimulation in Patients With Idiopathic Parkinson's Disease and Parkinsonian Syndromes
This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes, and to investigate strategies for optimal stimulation target selection. A prospective, single-center, double-blind, randomized, crossover design will be implemented. Participants will be recruited from outpatient and inpatient departments of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The primary hypothesis is that TIS will significantly improve motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The primary outcome measure will be the change in the MDS-UPDRS Part III score from baseline to post-stimulation.
This study is expected to provide direct evidence supporting the clinical application and target selection strategies of noninvasive deep brain stimulation for the treatment of Parkinson's disease and Parkinsonian syndromes.
Przegląd badań
Status
Rejestracja na zaproszenie
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Szacowany)
100
Faza
- Nie dotyczy
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Shanghai, Chiny
- Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Nie
Opis
Inclusion Criteria:
- Aged 40 to 80 years, diagnosed with idiopathic Parkinson's disease or Parkinsonian syndromes according to the Movement Disorder Society (MDS) diagnostic criteria.
- Receiving stable doses of levodopa or other dopaminergic medications for at least 4 weeks prior to enrollment, with a documented response to levodopa; medication regimen must remain unchanged during the study.
- Hoehn and Yahr (H&Y) stage ≤ 3 in the "ON" medication state.
- Normal cognitive function, defined as a Mini-Mental State Examination (MMSE) score ≥ 24.
- Able to maintain and cooperate with Parkinson's disease symptom diaries.
- Signed written informed consent.
Exclusion Criteria:
- Presence of other neurological or psychiatric disorders that may interfere with study participation or outcomes.
- Previous treatment with deep brain stimulation (DBS) or other invasive brain stimulation therapies.
- Orthopedic or other medical conditions that could affect gait or balance.
- Contraindications to MRI, such as claustrophobia or other factors making MRI unsuitable.
- History of taking antipsychotic, antidepressant, or other medications that may affect dopamine levels.
- Contraindications to electrical stimulation, such as implanted cardiac pacemakers or a history of epilepsy.
- History of electroconvulsive therapy (ECT).
- Severe comorbidities, including cardiovascular disease, respiratory disease, or hepatic/renal dysfunction.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: GPi TIS
Participants with PD or PDS receive TIS targeting the contralateral globus pallidus internus (GPi).
Each group consists of 10 patients with PD and 10 patients with PDS.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Eksperymentalny: STN TIS
Participants with PD or PDS receive TIS targeting the contralateral subthalamic nucleus (STN).
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Eksperymentalny: Putamen TIS
Participants with PD or PDS receive TIS targeting the contralateral putamen.
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Eksperymentalny: LHA TIS
Participants with PD or PDS receive TIS targeting the contralateral lateral hypothalamic area (LHA).
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Eksperymentalny: Dentate TIS
Participants with PD or PDS receive TIS targeting the ipsilateral cerebellar dentate nucleus.
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Efficacy of temporal interference stimulation (TIS) on motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part III is a rater-administered motor examination used to evaluate the severity of motor impairment in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 132, with lower scores indicating less severe motor symptoms.
Changes from baseline after real or sham stimulation will be analyzed and compared between groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Secondary motor outcome
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The UMSARS is a rater-administered scale used to assess disease severity in patients with Parkinsonian syndromes, particularly multiple system atrophy.
The total score ranges from 0 to 104, with a higher score indicating greater disease severity.
The change in UMSARS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Secondary motor outcome
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Freezing of Gait Questionnaire is used to assess the severity and frequency of freezing of gait in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 24, with a higher score indicating more severe freezing of gait.
The change in FOGQ score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Secondary motor outcome
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Berg Balance Scale is a rater-administered scale used to assess balance function and fall risk.
The total score ranges from 0 to 56, with a higher score indicating better balance function.
The change in Berg Balance Scale score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Hamilton Anxiety Rating Scale-14（HAMA-14）is a rater-administered scale used to assess the severity of anxiety symptoms.
The total score ranges from 0 to 56, with a higher score indicating more severe anxiety.
The change in HAMA-14 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Hamilton Depression Rating Scale-17（HAMD-17）is a rater-administered scale used to assess the severity of depressive symptoms.
The total score ranges from 0 to 52, with a higher score indicating more severe depression.
The change in HAMD-17 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Mini-Mental State Examination（MMSE）is a brief cognitive screening scale used to assess global cognitive function.
The total score ranges from 0 to 30, with a higher score indicating better cognitive function.
The change in MMSE score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Montreal Cognitive Assessment（MoCA）is a brief cognitive screening scale used to assess global cognitive function, particularly mild cognitive impairment.
The total score ranges from 0 to 30, with a higher score indicating better cognitive function.
The change in MoCA score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Non-Motor Symptoms Scale（NMSS）is a rater-administered scale used to assess the severity and frequency of non-motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 360, with a higher score indicating a greater non-motor symptom burden.
The change in NMSS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction（SCOPA-AUT）is a patient-reported scale used to assess autonomic symptoms in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 69, with a higher score indicating more severe autonomic dysfunction.
The change in SCOPA-AUT score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Parkinson's Disease Questionnaire-39 Summary Index（PDQ-39 SI）is a patient-reported scale used to assess health-related quality of life in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 100, with a higher score indicating poorer quality of life.
The change in PDQ-39 SI score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part I is used to assess non-motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 52, with a higher score indicating more severe non-motor symptom burden.
The change in MDS-UPDRS Part I score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part II is used to assess motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 52, with a higher score indicating greater motor-related impairment in daily living.
The change in MDS-UPDRS Part II score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Changes in resting-state EEG β-band oscillation power before and after stimulation
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Ramy czasowe: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Changes in whole-brain resting-state fMRI functional connectivity strength, with exploratory analyses focusing on the sensorimotor and basal ganglia networks, before and after stimulation
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Ramy czasowe: From baseline through study completion (up to 3 weeks)
|
The number and severity of all AEs and SAEs will be collected and monitored throughout the study to evaluate the safety and tolerability of the intervention.
|
From baseline through study completion (up to 3 weeks)
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
3 lipca 2026
Zakończenie podstawowe (Szacowany)
30 września 2026
Ukończenie studiów (Szacowany)
30 września 2026
Daty rejestracji na studia
Pierwszy przesłany
8 grudnia 2025
Pierwszy przesłany, który spełnia kryteria kontroli jakości
10 lipca 2026
Pierwszy wysłany (Rzeczywisty)
13 lipca 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
13 lipca 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
10 lipca 2026
Ostatnia weryfikacja
1 lipca 2026
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2025-622
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIE
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba Parkinsona
-
Peking University Third HospitalJeszcze nie rekrutacjaCentral Compartment Atopic Disease (CCAD)Chiny
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.ZakończonyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Japonia, Korea Południowa
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone
Badania kliniczne na AB Temporal Interference Stimulation
-
Zhujiang HospitalRekrutacyjnyZaburzenia świadomości | Minimalnie świadomy stan | Stan wegetatywnyChiny